Eli Lilly and Company (NYSE:LLY) Shares Sold by Bedrijfstakpensioenfonds Voor DE Media PNO

Bedrijfstakpensioenfonds Voor DE Media PNO decreased its position in Eli Lilly and Company (NYSE:LLY) by 11.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,000 shares of the company’s stock after selling 3,600 shares during the quarter. Eli Lilly and Company comprises approximately 2.5% of Bedrijfstakpensioenfonds Voor DE Media PNO’s holdings, making the stock its 10th largest position. Bedrijfstakpensioenfonds Voor DE Media PNO’s holdings in Eli Lilly and Company were worth $20,129,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Beck Bode LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at $15,036,000. AQR Capital Management LLC lifted its holdings in shares of Eli Lilly and Company by 17.3% during the second quarter. AQR Capital Management LLC now owns 474,552 shares of the company’s stock valued at $429,650,000 after purchasing an additional 70,122 shares during the last quarter. APG Asset Management US Inc. lifted its holdings in shares of Eli Lilly and Company by 0.8% during the second quarter. APG Asset Management US Inc. now owns 204,328 shares of the company’s stock valued at $186,831,000 after purchasing an additional 1,586 shares during the last quarter. APG Asset Management N.V. lifted its holdings in shares of Eli Lilly and Company by 6.7% during the second quarter. APG Asset Management N.V. now owns 703,220 shares of the company’s stock valued at $594,058,000 after purchasing an additional 44,133 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Eli Lilly and Company by 0.7% during the second quarter. Ameriprise Financial Inc. now owns 3,027,901 shares of the company’s stock valued at $2,741,832,000 after purchasing an additional 22,392 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on LLY shares. Wolfe Research started coverage on Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price for the company. Bank of America reaffirmed a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,002.22.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $766.00 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a fifty-two week low of $624.68 and a fifty-two week high of $972.53. The stock’s 50-day moving average is $776.31 and its two-hundred day moving average is $850.93. The firm has a market cap of $727.18 billion, a P/E ratio of 82.81, a PEG ratio of 1.56 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post 12.98 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Eli Lilly and Company announced that its board has initiated a stock repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.